07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

KalVista, Carbylan Therapeutics deal

Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81% stake in the combined company. The combined company will focus on KalVista’s pipeline, which includes KVD001 , an intravitreal...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Carbylan Therapeutics neurology news

Carbylan reduced headcount by 14 (82%) to three and suspended development of Hydros-TA. Carbylan is pursuing a strategic transaction, which may include a merger or acquisition of the company. In February, the company reported mixed...
08:00 , Feb 8, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/5 cls Carbylan Therapeutics Inc. (NASDAQ:CBYL) Leerink Partners Jason Gerberry Downgrade Market perform (from outperform) -75% $0.60 Gerberry also lowered...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Hydros-TA: Completed Phase III enrollment

Carbylan completed enrollment of 510 patients in the double-blind, international Phase III COR1.1 trial to compare Hydros-TA vs. TA and Hydros, which comprises bacterially derived HA chemically modified to form biodegradable hydrogel beads. Carbylan Therapeutics...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Financial News

Carbylan Therapeutics Inc completes IPO

Carbylan Therapeutics Inc . (NASDAQ:CBYL), Palo Alto, Calif.   Business: Neurology   Date completed: 2015-04-08   Type: IPO   Raised: $65 million   Shares: 13 million   Price: $5   Shares after offering: 24.2 million...
23:58 , Apr 8, 2015 |  BC Extra  |  Financial News

Carbylan raises $65M in downsized IPO

Carbylan Therapeutics Inc. (NASDAQ:CBYL) raised $65 million through the sale of 13 million shares at $5 in a downsized IPO on Wednesday. The price values the company at $121.2 million. In January, Carbylan proposed to...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Carbylan BioSurgery board of directors update

Carbylan BioSurgery Inc. , Palo Alto, Calif.   Business: Inflammation, Autoimmune   Appointed: Samuel Lynch as chairman; Lynch founded BioMimetic Therapeutics Inc. , which Wright Medical Group Inc. acquired  ...